Clinical Trial Update: Influence of Marker of Insulin Resistance Upon Hepatitis C Virus (HCV) Treatment Responses to PEG Intron and Rebetol Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating whether markers of insulin resistance influence virologic responses to PegIntron (peginterferon alfa-2b) and Rebetol (ribavi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PegIntron (pegylated interferon alfa-2b)
• Rebetol (ribavirin)

Snippet

Sponsor: Louisiana State University Health Sciences Center in New Orleans | Conditions: Chronic Hepatitis C | Phase 4 | Status: COMPLETED